生殖系BAP1突变筛查标准的患病率与初步验证
该研究对183例未选择的BAP1相关疾病患者进行血液采样和二代测序,检测生殖系BAP1突变并验证筛查标准。180例测序标本中5例检出致病或可能致病性生殖系BAP1突变,且均被筛查标准识别;间皮瘤患者中该突变患病率为4.4%(95%CI 1.1-11.1)。结论提示间皮瘤患者中该突变频率低,所提筛查标准可识别全部生殖系BAP1突变型间皮瘤患者。
要点
- 间皮瘤患者生殖系BAP1致病突变患病率为4.4%(95%CI 1.1-11.1)。
- 所提筛查标准成功识别全部生殖系BAP1突变型间皮瘤患者。
- 筛查标准有助于选择可从基因检测中获益的患者。
核心结论
- 间皮瘤患者中生殖系BAP1突变频率低。
- 所提筛查标准成功识别全部生殖系BAP1突变型间皮瘤患者。
研究设计与样本
- 研究纳入183例未选择的BAP1相关疾病患者,收集血样、癌症史和职业暴露信息。
- 对血样提取生殖系DNA,采用二代测序检测,并测试筛查标准。
主要发现
- 180例测序标本中5例检出致病或可能致病性生殖系BAP1突变,且均被筛查标准识别。
- 部分具有可疑遗传性有害突变特征的患者未检出生殖系BAP1突变。
- 间皮瘤患者中致病性生殖系BAP1突变患病率为4.4%(95%CI 1.1-11.1)。
关键数值与推荐
- 间皮瘤患者生殖系BAP1致病突变患病率为4.4%(95%CI 1.1-11.1)。
临床怎么用
- 所提筛查标准可用于选择可能受益于生殖系BAP1基因检测的患者。
局限性
- 筛查标准需未来验证和优化。
- 需寻找其他与间皮瘤及相关疾病相关的生殖系突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Inherited mutations are easily detected factors that influence the disease courses and optimal treatment strategies of some cancers. Germline mutations in BRCA1 associated protein 1 (BAP1) are associated with unique disease profiles in mesothelioma, atypical spitz nevi, and uveal melanoma, but the patient characteristics of an unselected population of BAP1 carriers identified by an ascertainment prevalence study are unknown. METHODS: We collected blood samples, cancer histories, and occupational exposures from 183 unselected patients with BAP1-related diseases. Clinical information for each patient was obtained from medical records. Germline DNA was extracted from blood samples and sequenced using a next-generation sequencing assay. We tested screening criteria developed to identify patients with a possible germline BAP1 mutation. RESULTS: Pathogenic or likely pathogenic germline BAP1 mutations were observed in 5 of 180 sequenced specimens and were exclusively found in patients identified by our screening criteria. Several patients with characteristics suspicious for a heritable deleterious mutation did not have a germline BAP1 mutation. The prevalence of pathogenic germline BAP1 mutations in patients with mesothelioma was 4.4% (95% confidence interval 1.1-11.1). CONCLUSIONS: Results from the first unselected prevalence ascertainment study of germline BAP1 alterations suggest that the frequency of this mutation is low among patients with mesothelioma. The proposed screening criteria successfully identified all patients with germline BAP1-mutant mesothelioma. These screening guidelines may assist physicians in selecting patients who would benefit from genetic testing. Future efforts should validate and refine these criteria and search for other germline mutations associated with mesothelioma and related diseases.
引用
- Zauderer MG, Jayakumaran G, DuBoff M, et al. Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. J Thorac Oncol. 2019. PMID: 31323388. doi:10.1016/j.jtho.2019.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。